<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04461015</url>
  </required_header>
  <id_info>
    <org_study_id>20-001570</org_study_id>
    <nct_id>NCT04461015</nct_id>
  </id_info>
  <brief_title>The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans</brief_title>
  <official_title>The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrian Vella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to help understand the relative importance of changes in
      insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to
      regulate metabolism and the body's ability to make glucose.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous glucose production (EGP)</measure>
    <time_frame>It will be quantified at 90, 180 and 270 minutes for the study with 0.4mU insulin infusion and compared to values obtained for the study with 0.8mU insulin infusion at the same timepoints</time_frame>
    <description>is calculated by tracer-based measurement and expressed per kg lean body mass</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>0.4mU Insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During the euglycemic clamp insulin will be infused at 0.4mU/Kg/Min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.8mU Insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During the euglycemic clamp insulin will be infused at 0.8mU/Kg/Min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4mU Insulin</intervention_name>
    <description>Insulin infused at 0.4 mU/Kg/min</description>
    <arm_group_label>0.4mU Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.8mU Insulin</intervention_name>
    <description>Insulin infused at 0.8 mU/Kg/min</description>
    <arm_group_label>0.8mU Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  We will recruit 15 otherwise healthy subjects using intramural and local extramural
             advertising after approval from the Mayo Clinic Institutional Review Board.
             Individuals who express interest in participating will be invited for a screening
             visit. Individuals with a BMI &lt; 19 or &gt; 28 kg/m2 will be excluded from the study to
             avoid potential confounding effects that may result from extreme leanness or from
             obesity. Subjects will have no known systemic illness, taking any medication that
             could affect glucose metabolism and no history of upper gastrointestinal surgery.

        Exclusion Criteria:

          -  Subjects &lt; 18 years of age or &gt; 40 years of age will not be studied to minimize the
             potential confounding effects of age on glucagon and insulin action. The subjects will
             not be taking medications that affect glucose metabolism (to be determined by PI) and
             have no history of chronic illness or upper gastrointestinal surgery. We are seeking
             to recruit subjects who do not have diabetes (fasting glucose &lt;100mg/dL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

